TIPIN is essential for chromosome stability and cell viability in BRCA1-deficient cells

Area of Science:

• Genetics
• Molecular Biology
• Cancer Research

Background:

• Mutations in the breast cancer type 1 susceptibility gene (BRCA1) are linked to hereditary breast cancer.
• Poly (ADP-ribose) polymerase (PARP) inhibitors are a revolutionary therapy for BRCA1-mutated breast cancer due to synthetic lethality.
• TIMELESS interacting protein (TIPIN) is crucial for DNA replication, damage checkpoints, and sister chromatid cohesion.

Purpose of the Study:

• To investigate a novel synthetic lethal interaction between BRCA1 and TIPIN.
• To explore the role of TIPIN deficiency in BRCA1-mutated cells and its implications for cancer therapy.

Main Methods:

• Cellular assays were used to examine the viability of cells with combined BRCA1 and TIPIN deficiencies.
• The impact of depleting Tumor protein p53 binding protein 1 (53BP1) and Ring finger protein 8 (RNF8) on cell viability was assessed.

Main Results:

• Cells deficient in both BRCA1 and TIPIN exhibit increased chromosomal aberrations, including breaks and radial chromosomes.
• Depletion of 53BP1 rescues the synthetic lethality in TIPIN/BRCA1-deficient cells, suggesting BRCA1-mediated homologous recombination (HR) repair is critical.
• Loss of viability in TIPIN/53BP1/BRCA1 triple-deficient cells upon RNF8 depletion indicates a role for RNF8-mediated sub-homologous recombination (sub-HR) pathway.

Conclusions:

• A synthetic lethal interaction exists between BRCA1 and TIPIN, highlighting TIPIN as a potential therapeutic target in BRCA1-mutated cancers.
• The findings elucidate the complex interplay between BRCA1, TIPIN, 53BP1, and RNF8 in maintaining genomic stability and DNA repair pathways.
• This research opens new possibilities for combination therapies by targeting multiple DNA repair pathways in BRCA1-mutated cancers.